In the wake of a harrowing inquest into the death of Oliver Robinson, a 34-year-old man whose struggle with mental health culminated in suicide, his family is advocating for more stringent regulations surrounding private cannabis prescriptions in the UK. Robinson’s use of medicinal cannabis, prescribed by Curaleaf Clinic, has come under scrutiny after the coroner determined it likely contributed to his demise, underscoring the urgent need for reform in a rapidly expanding sector.
A Life Marked by Struggles
Oliver Robinson’s battles with depression and addiction were well-documented, having been treated at the Priory, a private mental health facility, from 2019 until 2022. After exhausting traditional therapeutic avenues, he sought alternative treatments, which included medicinal cannabis, in a bid for relief. Tragically, by November 2023, the very medication intended to help him was identified as a significant barrier to his recovery.
The January inquest revealed that Robinson’s prescription, initiated in May 2022, was not only inappropriate but also detrimental to his mental health. Coroner Catherine McKenna highlighted that this prescription impeded his access to necessary psychiatric and addiction care, marking a pivotal moment in the discourse surrounding cannabis treatment for mental health issues.
The Family’s Campaign for Change
In light of these findings, Alexander Robinson, Oliver’s brother, has launched a campaign aimed at instituting stricter guidelines for private cannabis clinics. He is particularly concerned that vulnerable individuals might follow a similar path without adequate safeguards in place. “If things do not change he is not going to be the last,” he remarked, expressing fears for others who might find themselves in Oliver’s situation.
The legalisation of medicinal cannabis in 2018 was primarily driven by high-profile cases, such as that of a young boy with severe epilepsy, prompting a shift in how cannabis-based medicinal products (CBMPs) are prescribed. However, the current landscape reveals a concerning trend; private clinics, like Curaleaf, often prescribe unlicensed products that lack the rigorous approval processes typical of NHS medications.
The Regulation Gap
According to the Care Quality Commission (CQC), the majority of cannabis products dispensed in private settings are unlicensed, raising questions about efficacy and safety. In contrast, NHS prescriptions for licensed CBMPs numbered around 5,000 in 2023, primarily for severe epilepsy, multiple sclerosis, and chemotherapy-induced pain. With over 659,000 unlicensed cannabis products prescribed in 2024 alone, the gap between private and public healthcare practices is alarming.
Experts in the field, such as psychiatrist Dr Pavan Chahl, have voiced their concerns regarding the suitability of cannabis as a treatment for depression, citing a lack of evidence supporting its effectiveness while stressing its potential to exacerbate mental health issues. The existing guidelines from the British National Formulary clearly recommend against prescribing medicinal cannabis to individuals with a history of severe psychiatric disorders, a guideline that Oliver’s case starkly exemplifies.
The Personal Toll of a Failing System
Oliver’s mental health struggles were compounded by a history of substance misuse, including cannabis use since adolescence. After his second discharge from the Priory, he returned to cannabis after a chance encounter with a forgotten stash, believing it provided a reprieve from his depressive symptoms. However, his family soon noticed concerning changes in his behaviour, with violent outbursts and erratic actions leading to significant family distress. The police were frequently called due to the escalating situation.
Despite being referred to an NHS psychiatrist, Oliver resisted the diagnosis of bipolar disorder and cannabis dependency, leading to a tragic downward spiral that culminated in his death. The inquest revealed various failings in his care, including reliance on outdated medical records and a lack of communication between his private and NHS healthcare providers.
Following the coroner’s findings, Curaleaf, while expressing condolences to the family, has committed to improving its clinical governance in light of the inquest. However, the overarching question remains whether enough is being done to protect patients within the private cannabis sector.
Why it Matters
The tragic case of Oliver Robinson highlights a critical intersection between mental health care and emerging treatment modalities like medicinal cannabis. As the sector continues to grow, the call for enhanced regulation is not merely a response to one family’s loss but a necessary step towards safeguarding the mental well-being of countless individuals seeking help. Ensuring that vulnerable patients receive appropriate care and oversight is paramount, as the implications of inadequate regulation could lead to further tragedies. The need for systematic reform in private cannabis prescriptions is both urgent and essential for the future of mental health treatment in the UK.
